# Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

> **NCT02335944** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 177 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Nazartinib

## Key facts

- **NCT ID:** NCT02335944
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-13
- **Primary completion:** 2020-11-10
- **Final completion:** 2020-11-10
- **Target enrollment:** 177 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02335944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02335944, "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02335944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*